



**Medical Policy
Artificial Pancreas Device System**

Document Number: 039

	Commercial and Qualified Health Plans	MassHealth
Authorization required	X	X
No Prior Authorization		

Overview

The purpose of this document is to describe the guidelines AllWays Health Partners utilizes to determine medical necessity for an artificial pancreas device system.

Coverage Guidelines

Medical necessity for an artificial pancreas device system is determined through McKesson’s InterQual® criteria. To access the criteria, log in to AllWays Health Partners’ provider website at allwaysprovider.org and click the InterQual® Criteria Lookup link under the Resources Menu.

To summarize, AllWays Health Partners may authorize coverage of an artificial pancreas system if a member meets **ALL** of the following criteria:

1. A history of Type 1 diabetes mellitus
2. Supporting clinical documentation and prescription by an Endocrinologist
3. a) A history of recurrent hypoglycemia or nocturnal hypoglycemia or hypoglycemia unawareness

OR

- b) Two consecutive A1c levels over 7% within the last 12 months

Exclusions

1. When the member does not meet the coverage criteria;
2. The member has diabetes mellitus type 2
3. The member has gestational diabetes
4. Replacement or repair or units or associated equipment when lost or damaged secondary to improper care or neglect;
5. The device is not an FDA-approved artificial pancreas device system
6. The member has a functioning model and a newer or upgraded model is not medically necessary

Definitions

Artificial Pancreas Device System: An artificial pancreas device system (APDS) is a series of devices, eg, a continuous glucose monitor (CGM), blood glucose device and an insulin pump, plus a computer algorithm that communicates with all of the devices. The goal of the APDS is to automatically monitor glucose levels and adjust insulin levels. These systems are also called closed-loop systems or autonomous systems for glucose control.

CPT/HCPC Codes

Authorized CPT/HCPCS Codes	Code Description

S1034	Artificial pancreas device system (e.g., low glucose suspend [LGS] feature) including continuous glucose monitor, blood glucose device, insulin pump and computer algorithm that communicates with all of the devices
S1035	Sensor; invasive (e.g., subcutaneous), disposable, for use with artificial pancreas device system
S1036	Transmitter; external, for use with artificial pancreas device system
S1037	Receiver (monitor); external, for use with artificial pancreas device system

Effective

December 2018: Annual update

May 2018: Added codes.

January 2018: Effective date.

References

Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. *JAMA* 2016;316(13):1407-1408. PMID 27629148

Beklari E et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. *BMJ* 2018 April 18; 361: k1310

Bock MD, Dart J, Roy A, et al. Exploration of the Performance of a Hybrid Closed Loop Insulin Delivery Algorithm That Includes Insulin Delivery Limits Designed to Protect Against Hypoglycemia. *Journal of Diabetes Science and Technology* 2016;11(1):68–73.

Boughton CK, Hovorko R. Is an artificial pancreas (closed loop system) for Type 1 diabetes effective? *Diabetic Med* 2018 Sept DOI 10.1111/dme. 13816

Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. *Diabetes Technology & Therapeutics* 2017;19(3):155-163. doi:10.1089/dia.2016.0421.

Food and Drug Administration (FDA). Types of Artificial Pancreas Device Systems. <https://www.fda.gov/medicaldevices/productsandmedicalprocedures/homehealthandconsumer/consumerproducts/artificialpancreas/ucm259555.htm>. Accessed October 12, 2017.

Hayes, Inc. Search & Summary Report. MiniMed 670G System (Medtronic, Inc.) <http://www.hayesinc.com>. Published October 13, 2016. Accessed October 2, 2017.

Ly TT, Weinzimer SA, Maahs DM, et al. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. *Pediatric Diabetes* 2016;18(5):348–55

Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? *J Diabetes Sci Technol*. 2016;10(3):714-723. PMID 26589628



Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. *Diabetes Care* 2008;31(5):934–9.